

Publication list

Original papers

1. **Fehr,T.**, Bachmann,M.F., Bluethmann,H., Kikutani,H., Hengartner,H., & Zinkernagel,R.M. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. *Cell. Immunol.* 168, 184-192 (1996).
2. Holtschke,T., Löhler,J., Kanno,Y., **Fehr,T.**, Giese,N., Rosenbauer,F., Lou,J., Knobloch,K.-P., Gabriele,L., Waring,J.F., Bachmann,M.F., Zinkernagel,R.M., Morse III,H.C., Ozato,K., & Horak,I. Immunodeficiency and chronic myelogenous leukemia - like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* 87, 307-317 (1996).
3. Bachmann,M.F., Lutz,M.B., Layton,G.T., Harris,S.J., **Fehr,T.**, Hengartner,H., Zinkernagel,R.M., & Ricciardi-Castagnoli,P. Dendritic cells process exogenous viral proteins and virus-like particles for MHC class I presentation to CD8+ cytotoxic T lymphocytes. *Eur. J Immunol.* 26, 2595-2600 (1996).
4. **Fehr,T.**, Bachmann,M.F., Bucher,E., Kalinke,U., Di Padova,F.E., Lang,A.B., Hengartner,H., & Zinkernagel,R.M. Role of repetitive antigen patterns for induction of antibodies against antibodies. *J. Exp. Med.* 185, 1785-1792 (1997).
5. Bachmann,M.F., **Fehr,T.**, Freer,G., Hengartner,H., & Zinkernagel,R.M. Correlation of tolerogenicity of a viral antigen with its immunogenicity. *J. Immunol.* 158, 5106-5111 (1997).
6. **Fehr,T.**, Schoedon,G., Odermatt,B., Holtschke,T., Schneemann,M., Bachmann,M.F., Mak,T.W., Horak,I., & Zinkernagel,R.M. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. *J. Exp. Med.* 185, 921-931 (1997).
7. Toume,S., Miyazaki,T., Oxenius,A., Klein,L., **Fehr,T.**, Kyewski,B., Benoist,C., & Mathis,D. Selection of a broad repertoire of CD4+ T cells in H-2M^{a0/0} mice. *Immunity* 7, 187-195 (1997).
8. **Fehr,T.**, Naim,H.Y., Bachmann,M.F., Ochsenbein,A.F., Spielhofer,P., Bucher,E., Hengartner,H., Billeter,M.A., & Zinkernagel,R.M. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. *Nat. Med.* 4, 945-948 (1998).
9. **Fehr,T.**, Skrastina,D., Pumpens,P., & Zinkernagel,R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. *Proc. Natl. Acad. Sci. U. S. A.* 95, 9477-9481 (1998).
10. **Fehr,T.**, Rickert,R.C., Odermatt,B., Roes,J., Rajewsky,K., Hengartner,H., & Zinkernagel,R.M. Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19. *J Exp. Med.* 188, 145-155 (1998).
11. Spielhofer,P., Bächli,T., **Fehr,T.**, Christiansen,G., Cattaneo,R., Kaelin,K., Billeter,M.A., & Naim,H.Y. Chimeric measles viruses with a foreign envelope. *J Virol.* 72, 2150-2159 (1998).
12. Ochsenbein,A.F., **Fehr,T.**, Lutz,C., Suter,M., Brombacher,F., Hengartner,H., & Zinkernagel,R.M. Control of early viral and bacterial distribution and disease by natural antibodies. *Science* 286, 2156-2159 (1999).
13. **Fehr,T.**, Lopez-Macias,C., Odermatt,B., Torres,R.M., Schubart,D.B., O'Keefe,T.L., Matthias,P., Hengartner,H., & Zinkernagel,R.M. Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules. *Int. Immunol.* 12, 1275-1284 (2000).
14. Pinschewer,D.D., Ochsenbein,A.F., **Fehr,T.**, & Zinkernagel,R.M. Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine. *Transplantation* 72, 712-719 (2001).
15. Ammann,P., **Fehr,T.**, Minder,E.I., Gunter,C., & Bertel,O. Elevation of troponin I in sepsis and septic shock. *Intensive Care Med.* 27, 965-969 (2001).
16. **Fehr,T.**, Bossart,W., Wahl,C., & Binswanger,U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. *Transplantation* 73, 608-611 (2002).

17. Fehr, T., Knoflach, A., Ammann, P., Pei, P., & Binswanger, U. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin. Nephrol.* 59, 35-39 (2003).
18. Ammann, P., Maggiorini, M., Bertel, O., Haenseler, E., Joller-Jemelka, H.I., Oechslin, E., Minder, E.I., Rickli, H., & Fehr, T. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. *J. Am. Coll. Cardiol.* 41, 2004-2009 (2003).
19. Fehr, T., Riehle, H.M., Nigg, L., Gruter, E., Ammann, P., Renner, E.L., & Ambuhl, P.M. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. *Am. J. Kidney Dis.* 42, 193-201 (2003).
20. Rickli, H., Benou, K., Ammann, P., Fehr, T., Brunner-La Rocca, H.P., Petridis, H., Riesen, W., & Wuthrich, R.P. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. *Clin. Nephrol.* 61, 98-102 (2004).
21. Ammann, P., Brunner-La Rocca, H., Fehr, T., Munzer, T., Sagmeister, M., Angehrn, W., & Rickli, H. Coronary anatomy and left ventricular ejection fraction in patients with type 2 diabetes admitted for elective coronary angiography. *Catheter. Cardiovasc. Interv.* 62, 432-438 (2004).
22. Fehr, T., Kahlert, C., Fierz, W., Joller-Jemelka, H.I., Riesen, W.F., Rickli, H., Wuthrich, R.P., & Ammann, P. Statin-induced immunomodulatory effects on human T cells in vivo. *Atherosclerosis* 175, 83-90 (2004).
23. Fehr, T., Ammann, P., Garzoni, D., Korte, W., Fierz, W., Rickli, H., & Wuthrich, R.P. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. *Kidney Int.* 66, 1206-1211 (2004).
24. Fehr, T., Takeuchi, Y., Kurtz, J., Wekerle, T., & Sykes, M. Early regulation of CD8 T cell alloreactivity by CD4(+)CD25(-) T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8(+) T cells, precluding a role for sustained regulation. *Eur J Immunol.* 35, :2679-2690 (2005).
25. Fudaba, Y., Spitzer, T.R., Shaffer, J., Kawai, T., Fehr, T., Delmonico, F., Preffer, F., Tolkoff-Rubin, N., Dey, B., Saidman, S.L., Kraus, A., Bonnefoix, T., McAfee, S., Power, K., Kattleman, K., Colvin, R.B., Sachs, D.H., Cosimi, A.B., Sykes, M. Myeloma responses and tolerance following combined kidney and non-myeloablative marrow transplantation: in vivo and in vitro analyses. *Am J Transplant.* 6, 2121-2133 (2006).
26. Fehr, T., Garzoni, D., Staub, T., Binet, I. & Wuthrich, R.P. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. *Kidney Blood Press Res.* 29, 175-181 (2006).
27. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. *J Am Soc Nephrol.* 17:2919-2927 (2006).
28. Nigg-Calanca L, Fehr T, Jochum W, Fischer-Vetter J, Mullhaupt B, Wuthrich RP, Ambuhl PM. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. *J Clin Virol.* 39:54-58 (2007).
29. Yung GP, Valli PV, Starke A, Mueller RJ, Fehr T, Cesar-Ozpamir M, Schanz U, Weber M, Wüthrich RP, Seebach JD, Stussi G. Flow cytometric measurement of ABO antibodies in ABO-incompatible living donor kidney transplantation. *Transplantation* 84(12 Suppl):S20-23 (2007).
30. Haspot F, Fehr T, Gibbons C, Zhao G, Hogan T, Honjo T, Freeman G, Sykes M. Peripheral deletional tolerance of alloreactive CD8, but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. *Blood.* 112:2149-2155 (2008).
31. Fehr T, Haspot F, Mollov J, Chittenden M, Hogan T, Sykes M. Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells and MHC class II. *J Immunol.* 181:165-173 (2008).
32. Henz S, Maeder M, Huber S, Schmid M, Loher M, Fehr T. Influence of Drugs and Comorbidity on Serum Potassium in 15'000 Consecutive Hospital Admissions. *Nephrol Dial Transplant.* 23:3939-3945 (2008).

33. **Fehr T**, Wang S, Haspot F, Kurtz J, Blaha P, Hogan T, Chittenden, Wekerle T, Sykes M. Rapid, deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells. *J Immunol.* 181:4371-4380 (2008).
34. Valli PV, Puga Yung G, Schulz-Huotari C, Kaup N, Gungör T, Ambühl PM, Weber M, **Fehr T**, Schanz U, Seebach JD, Stussi G. Changes of circulating antibody levels induced by ABO antibody absorption for ABO Incompatible Kidney Transplantation. *Am J Transplant.* 9:1072-1080 (2009).
35. **Fehr T**, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment for chronic antibody-mediated kidney allograft rejection. *Transplantation* 87:1837-1841 (2009).
36. Grimmelt AC, Cohen CD, **Fehr T**, Serra AL, Wuethrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. *Clin Nephrol.* 71:125-9 (2009).
37. Gianella S, Haeberli L, Joos B, Ledergerber B, Wüthrich RP, Weber R, Kuster H, Hauser PM, **Fehr T**, Mueller NJ. Molecular evidence of interhuman transmission in an outbreak of *Pneumocystis jirovecii* pneumonia among renal transplant recipients. *Transpl Infect Dis.* 12:1-10 (2010).
38. Neusser MA, Kraus AK, Regele H, Cohen CD, **Fehr T**, Kerjaschki D, Wüthrich RP, Penfold ME, Schall T, Segerer S. The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. *Kid Int* 77:801-808 (2010).
39. Starke A, Lindenmeyer MT, Segerer S, Neusser MA, Rüsi B, Schmid DM, Cohen CD, Wüthrich RP, **Fehr T**, Waeckerle-Men Y. Renal tubular PD-L1 (CD274) suppresses alloreactive human T cell responses. *Kid Int* 78:38-47 (2010).
40. **Fehr T**, Lucas CL, Kurtz J, Onoe T, Zhao G, Hogan T, Vallot C, Rao A, Sykes M. A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. *Blood* 115:1280-1287 (2010).
41. Altmann DR, Korte W, Maeder MT, **Fehr T**, Haager P, Rickli H, Kleger GR, Rodriguez R, Ammann P. Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis. *PLoS ONE* 5 (e9017):1-5 (2010).
42. Oetttl T, Zuliani E, Gasper A, Hopfer H, Dickenmann M, **Fehr T**. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection. *Transplantation* 27;89(6):702-6 (2010).
43. Schorn R, Höhne M, Meerbach A, Bossart W, Wüthrich RP, Schreier E, Müller NJ, **Fehr T**. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. *Clin Inf Dis* 51:307-314 (2010).
44. Riethmüller S, Ferrari-Lacraz S, Müller MK, Raptis DA, Hadaya K, Rüsi B, Laube G, Schneiter G, **Fehr T**, Villard J. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. *Transplantation* 90: 160-167 (2010).
45. Fries C, Roos M, Gaspert A, Vogt P, Salomon F, Wüthrich RP, Vavricka SR, **Fehr T**. Atheroembolic disease--a frequently missed diagnosis: results of a 12-year matched-pair autopsy study. *Medicine (Baltimore)* 89:126-32 (2010).
46. Tian Y, Chen J, Gaspert A, Segerer S, Clavien PA, Wüthrich RP, **Fehr T**. Kidney transplantation in mice using left and right kidney grafts. *J Surg Res* 163: e91-7 (2010).
47. Lehmann K, Müller MK, Schiesser M, Wildi S, **Fehr T**, Wüthrich RP, Clavien PA, Weber M. Treatment of ureteral complications after kidney transplantation with native ureteropyelostomy reduces the risk of pyelonephritis. *Clin Transplant* 25: 201-6 (2011).
48. Cippà PE, Kraus AK, Edenhofer I, Segerer S, Chen J, Hausmann M, Liu Y, Guimezanes A, Bardwell PD, Wüthrich RP, **Fehr T**. The BH3-mimetic ABT-737 inhibits allogeneic immune responses. *Transpl Int* 24: 722-32 (2011).

49. Fritzsche FR, Pianca S, Gaspert A, Varga Z, Wang L, Farrell MP, Chen XB, Hirsch HH, Springer E, **Fehr T**, Myles J, Tubbs R, Moch H. Silver-enhanced in situ hybridization for detection of polyomavirus DNA in patients with BK virus nephropathy. *Diagn Mol Pathol* 20:105-10 (2011).
50. Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, **Fehr T**, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP. Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. *Ann Hum Genet.* 75: 639-647 (2011).
51. Schmid-Mohler G, Albiez T, Schäfer-Keller P, **Fehr T**, Biotti B, Spirig R. [In-patient education after renal transplantation]. *Pflege* 24: 317-28 (2011).
52. Wahrmann M, Schiemann M, Marinova L, Körmöczi GF, Derfler K, **Fehr T**, Stussi G, Böhmig GA. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. *Nephrol Dial Transplant.* 27(5):2122-92 (2012).
53. Varga Z, Gaspert A, Behnke S, von Teichman A, Fritzsche F, **Fehr T**. Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. *Pathol Int.* 62: 254-63 (2012).
54. Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, Huber C, Gogineni E, Oka S, Goto N, **Fehr T**, Gianella S, Konrad R, Sing A, Kovacs JA. Outbreaks of pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of pneumocystis: implications for transmission and virulence. *Clin Infect Dis.* 54: 1437-44 (2012).
55. Cippà PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, Wekerle T, Wüthrich RP, **Fehr T**. Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. *Cell Death Dis.* 19; 3:e299 (2012).
56. Maeder MT, Rickli H, Pfisterer ME, Muzzarelli S, Ammann P, **Fehr T**, Hack D, Weilenmann D, Dieterle T, Kiencke S, Estlinbaum W, Brunner-La Rocca HP; TIME-CHF Investigators. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. *Am Heart J.* 163: 407-14 (2012).
57. Greiner M, Cusini A, Ruesch M, Schiesser M, Ledergerber B, **Fehr T**, Mueller NJ. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. *Infection.* 40(6):669-75 (2012).
58. Varga Z, Gaspert A, Behnke S, von Teichman A, Fritzsche F, **Fehr T**. Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. *Pathol Int.* 62(4):254-63 (2012).
59. Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, Huber C, Gogineni E, Oka S, Goto N, **Fehr T**, Gianella S, Konrad R, Sing A, Kovacs JA. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. *Clin Infect Dis.* 54(10):1437-44 (2012).
60. Schmid-Mohler G, **Fehr T**, Witschi P, Albiez T, Biotti B, Spirig R. [Development of an evidence-based self-management programme for patients in the first year after renal transplantation with a focus on prevention of weight gain, physical exercise and drug adherence]. *Pflege* 26(3):191-205 (2013).
61. Koller MT, van Delden C, Müller NJ, Baumann P, Lovis C, Marti HP, **Fehr T**, Binet I, De Geest S, Bucher HC, Meylan P, Pascual M, Steiger J. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. *Eur J Epidemiol.* 28(4):347-55 (2013).
62. Kraus AK, Cippà PE, Gaspert A, Chen J, Edenhofer I, Wüthrich RP, Lindenmeyer M, Segerer S, **Fehr T**. Absence of donor CD40 protects renal allograft epithelium and preserves renal function. *Transpl Int.* (5):535-44 (2013).

63. Cippà PE, Kamarashev J, Chen J, Kraus AK, Segerer S, Feldmeyer L, **Fehr T**. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. *Apoptosis*. 18(3):315-23 (2013).
64. Cippà PE, Gabriel SS, Chen J, Bardwell PD, Bushell A, Guimezanes A, Kraus AK, Wekerle T, Wüthrich RP, **Fehr T**. Targeting apoptosis to induce stable mixed haematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice. *Blood*. 122: 1669-77 (2013).
65. Burkhalter H, Brunner DP, Wirz-Justice A, Cajochen C, Weaver TE, Steiger J, **Fehr T**, Venzin RM, De Geest S. Validation of a single item to assess daytime sleepiness for the Swiss Transplant Cohort Study. *Prog Transplant*. 23:220-8 (2013).
66. Burkhalter H, Brunner DP, Wirz-Justice A, Cajochen C, Weaver TE, Steiger J, **Fehr T**, Venzin RM, De Geest S. Self-reported sleep disturbances in renal transplant recipients. *BMC Nephrol*. 14: 220 (2013).
67. Raess M, Fröhlich G, Roos M, Rüsi B, Wilhelm MJ, Noll G, Ruschitzka F, **Fehr T**, Enseleit F. Donor-specific anti-HLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation. *Transpl Int*. 26: 1097-107 (2013).

Case reports

68. **Fehr, T.**, Rickli, H., Müller, J., Wüthrich, R.P., & Ammann, P. Kidney at risk: 11-year course of renal artery stenosis. *Nephrol. Dial. Transplant*. 18, 443-444 (2003).
69. **Fehr, T.**, Jacky, E., & Bachli, E.B. Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia. *Ann. Hematol*. 82, 193-196 (2003).
70. Maeder, M., **Fehr, T.**, August, B., & Galeazzi, R.L. Schwere Hypokaliämie mit Pseudo-QTc Verlängerung. *Schweiz. Med. Forum* 44, 1066-1067 (2003).
71. **Fehr, T.**, Zimmermann, D.R., Wüthrich, R.P., & Ammann, P. A young renal transplant recipient with unexplained resting sinus tachycardia, hypertension and beta-blocker resistance. *Nephrol. Dial. Transplant*. 19, 1646-1649 (2004).
72. Staub-Zahner T, Garzoni D, Fretz C, Lampert C, Ohlschlegel C, Wüthrich RP, **Fehr T**. Pseudotumor of gout in the patella of a kidney transplant recipient. *Nat Clin Pract Nephrol*. 3, 345-349 (2007).
73. Trachsler J, Gaspert A, Previsdomini M, Wüthrich RP, **Fehr T**. Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome. *Nephrol. Dial. Transplant*. PLUS 5:307-309 (2008).
74. Gaspert A, Lüthi B, Mueller NJ, Bossart W, Heim A, Wüthrich RP, **Fehr T**. Subacute allograft dysfunction with dysuria and hematuria in a kidney transplant recipient. *Am J Kid Dis*. 54:154-158 (2009).
75. Müller NJ, Weisser M, **Fehr T**, Wüthrich RP, Müllhaupt B, Lehmann R, Imhof A, Aubert JD, Genoni M, Kunz R, Weber M, Steiger J. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. *Transpl Infect Dis* 12: 54-69 (2010).
76. Cusini A, Günthard HF, Stussi G, Schwarz U, **Fehr T**, Grueter E, Meerbach A, Bossart W, Schaer DJ, Rudiger A. Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. *Infection* 38: 423-6. (2010).
77. Breitenstein A, Stumpe KDN, Gannt R, **Fehr T**, Etter C. Calcineurin-inhibitor pain syndrome after kidney transplantation - a rare but disabling condition. *NDT Plus* (2010).
78. Reser D, Tavakoli R, **Fehr T**. Erste schweizerische zweizeitige Herz-Nieren-Transplantation mit Organen desselben Donors. *Schweiz Med Forum* 10: 670–672 (2010).
79. Fritschi BC, Trachsler J, Varga Z, Binet I, **Fehr T**. Iatrogenic nephrocalcinosis with acute renal failure: an underestimated complication after parathyroidectomy? *NDT Plus* (2010).
80. Schleich A, **Fehr T**, Gaspert A, Wüthrich RP, Mohebbi N. Unexpected deterioration of graft function after combined kidney and pancreas transplantation. *Clin Kidney J*. 6, 228-230 (2013).

Reviews

81. **Fehr T** Cholesterinembolien. *Cardiovasc* 2, 52-59 (2003).
82. Maeder M., Klein M., **Fehr T**, & Rickli H. Contrast nephropathy: review focusing on prevention. *J. Am. Coll. Cardiol.* 44, 1763-1771 (2004).
83. **Fehr,T.** & Sykes,M. Tolerance induction in clinical transplantation. *Transpl. Immunol.* 13, 117-130 (2004).
84. Maeder,M., **Fehr,T.**, Rickli,H., & Ammann P. Sepsis-associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides. *Chest* 129, 1349-1366 (2006).
85. **Fehr,T.**, Gaspert,A., Varga,Z., Bosshard,A., & Ambühl,P.M. Hepatitis B- und -C-assoziierte Glomerulonephritiden. *Der Nephrologe* 2, 37-43 (2007).
86. **Fehr,T.** & Sykes,M. Clinical experience with mixed chimerism to induce transplantation tolerance. *Transpl Int* 21, 1118-1135 (2008).
87. **Fehr T**, Wüthrich RP. Monoklonale Antikörpertherapie bei der Organtransplantation. *Schweiz Med Forum* 8:204–209 (2008)
88. Wüthrich RP, **Fehr T**. Probleme nach Nierentransplantation: Ein Drittel der Todesfälle geht auf kardiovaskuläre Komplikationen zurück. *Cardiovasc* 1, 8-12 (2008)
89. Elke B, Ludin S, **Fehr T**. Proteinurie. *Praxis (Bern 1994)* 97:811-818 (2008)
90. Elke B, Ludin S, **Fehr T**. Mikro- und Makrohämaturie bei Erwachsenen. *Praxis (Bern 1994)* 97:755-761 (2008)
91. Elke B, Gaspert A, **Fehr T**. Akute/Subakute Niereninsuffizienz. *Praxis (Bern 1994)* 97:1057-1066 (2008)
92. Bonani M, **Fehr T**. Chronische Niereninsuffizienz in der Hausarztpraxis. *Praxis (Bern 1994)* 98:823-832 (2009)
93. Cippà PE, **Fehr T**. Medikamentös induzierte Niereninsuffizienz - Wenn Arzneien an die Nieren gehen. *Hausarzt Praxis* 10:12-14 (2010)
94. **Fehr T**, Stussi G. ABO-incompatible kidney transplantation. *Curr Opin Organ Transplant.* 17(4):376-85 (2012).
95. **Fehr T**, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. *Transpl Int.* 25(6):623-32 (2012).

Editorials and comments

96. Ammann,P., Pfisterer,M., **Fehr,T.**, & Rickli,H. Raised cardiac troponins (Editorial). *BMJ* 328, 1028-1029 (2004).
97. **Fehr T**, Ambuhl PM. Chronic hepatitis virus infections in patients on renal replacement therapy (Editorial). *Nephrol. Dial. Transplant.* 19, 1049-1053 (2004).
98. **Fehr,T.** & Ochsenbein,A.F. Outcome of the antibody response: a question of antigen dose and distribution. *Trends Immunol.* 25, 165-166 (2004).
99. **Fehr T**, Bardwell P, Sykes,M. Commentary on „Use of skin grafting to demonstrate tolerance before kidney transplantation without immunosuppression in the recipient of a previous bone marrow transplant“ by Ravanan et al. *Transplantation* 80: 1359-1360 (2005).
100. Cippà PE, **Fehr T** Spontaneous tolerance in kidney transplantation--an instructive, but very rare paradigm. *Transpl Int.* 24: 534-5 (2011).
101. van Gelder T; ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. *Transpl Int.* 24: 1135-41 (2011).
102. **Fehr T**, Cohen CD. Predicting an allograft's fate. *Kidney Int.* 80: 1254-5 (2011).

103. **Fehr T.** Rheuma und Organtransplantation. Rheuma Schweiz. 1: 36-40 (2013).

Book chapters

104. **Fehr, T.** & **Wüthrich, R.P.** Wasser-, Elektrolyt- und Säure/Basestörungen in Differenzialdiagnose Innerer Krankheiten, Edn. 19. ed. Siegenthaler, W. 902-955 (Thieme Verlag, 2005).

105. **Fehr, T.** & **Wüthrich, R.P.** Water, electrolyte and acid-base disorders in Differential diagnosis in Internal Medicine, Edn. 19. ed. Siegenthaler, W. (Thieme edition, 2007).

106. **Fehr, T.** & **Wüthrich, R.P.** Wasser-, Elektrolyt- und Säure/Basestörungen in Differenzialdiagnose Innerer Krankheiten, Edn. 20. ed. Battegay E. 882-940 (Thieme Verlag, 2012)